Biopharmaceutical New Technologies (BioNTech) and Pfizer have released additional details regarding their collaboration to advance the mRNA COVID-19 vaccine candidate BNT162. Pfizer will pay up to $748 million to BioNTech.
MilliporeSigma announced that the U.S. Patent and Trademark Office has granted the company's patent for CRISPR-chrom technology. This award is the second CRISPR patent granted to the company in the U.S. and its 23rd CRISPR-related patent worldwide.
Boehringer Ingelheim announced that it is significantly increasing support for the fight against COVID-19, particularly by adding a number of strategic collaboration partners for therapy development.
Avectas has received a patent for its Solupore cell engineering technology.
Biopharmaceutical firm Arrakis Therapeutics has inked a license agreement with Roche to collaborate on research of Roche's RNA-targeted small-molecule drugs.
Clinical artificial intelligence (AI) software developer Mendel said it has developed an AI-based search engine that can analyze more than 50,000 novel coronavirus research papers and answer COVID-19-related questions.
After deciding to postpone its annual scientific meeting due to COVID-19, The American Association for Clinical Chemistry (AACC) has rescheduled the meeting and clinical lab expo for December 13-17 in Chicago
Gladstone Institutes is seeking donations to mobilize resources and start research projects to help fight the COVID-19 pandemic.
Applied DNA and Takis Biotech have added a fifth candidate to their COVID-19 vaccine development program, increasing the chances of a successor emerging.
Modalis Therapeutics has licensed intellectual property (IP) from CRISPR-related gene-editing company Editas Medicine.